TRISTEL PLC

Regulatory Filings • Jan 18, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8395V

Tristel PLC

18 January 2013

Tristel plc

("Tristel" or the "Group")

Tristel Wipes System obtains regulatory approval in China

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that is has now received a licence from the Health Department of the People's Republic of China to import and sell the Tristel Wipes System.

The Tristel Wipes System is a practical and highly effective way to decontaminate and disinfect non-lumened medical devices. The system achieves high-level disinfection in less than two minutes. It comprises three individual wipes that perform the functions of cleaning the device, disinfecting the device and then rinsing it to remove any chemical residues before use on the next patient.  It also incorporates a traceability process to provide the user with an audit trail.  The Wipes System has been protected by patent in China since July 2011.

The Wipes System decontaminates flexible endoscopes used for ear, nose and throat investigations; intra-cavity ultrasound probes used in urology, obstetrics and gynaecology; instrumentation used in IVF clinics; ultrasound probes that image the heart in cardiology, and in ophthalmology. Some of the major markets in which the Wipes System has established a significant presence are the United Kingdom, Germany, France, Italy, Russia and Australia.

Tristel's worldwide sales of the Wipes System in the financial year ended 30 June 2012 had increased by 56.6% to £3.4m (2011: £2.2m), and contributed to total sales of £10.9m across the Group.

Tristel CEO, Paul Swinney, commented: "We identified a number of years ago that there is a family of small heat-sensitive instruments that have been largely neglected by infection control companies. The instruments are short and simple in construction because they only have to reach into the smaller cavities of the body, like the nasal passage or the vagina. In contrast, our competitors have focused upon digestive and respiratory medicine where instruments have to be larger to reach the parts of the body that they need to investigate, for example the colon. 

"We believe the Wipes System has already established itself as the 'gold standard' for the decontamination of these smaller instruments in the countries where it has obtained regulatory approval.  With the licence we can now seek to replicate this success in China - the world's most populous and fastest growing healthcare market." 

For further information please contact:       

## Tristel plc	Tel: 01638 721 500
Paul Swinney, Chief Executive Officer
Liz Dixon, Finance Director
Walbrook PR Ltd	Tel: 020 7933 8780
Paul McManus	Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com
Lianne Cawthorne	Mob: 07854 391 303 or lianne.cawthorne@walbrookpr.com
finnCap	Tel: 020 7600 1658
Geoff Nash (Corporate Finance)
Charlotte Stranner (Corporate Finance)
Simon Starr (Corporate Broking)

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCDMGMMNNKGFZM